Who are Ecabet 3.70%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): methotrexate + misoprostol, Zinc-l-carnosine, CHOP Plus Famotidine, Ibuprofen/famotidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ecabet-3-70.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ecabet 3.70% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ecabet 3.70% (Ecabet 3.70%) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gastroprotective agent. Area: Gastrointestinal.

phase 2 Gastroprotective agent Gastrointestinal Small molecule Live · refreshed every 30 min

Target snapshot

Ecabet 3.70% (Ecabet 3.70%) — Bausch & Lomb Incorporated. Ecabet is a gastroprotective agent that acts as a mucosal protective agent.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ecabet 3.70% TARGET	Ecabet 3.70%	Bausch & Lomb Incorporated	phase 2	Gastroprotective agent
methotrexate + misoprostol	methotrexate + misoprostol	Wiebe, Ellen, M.D.	marketed	Antimetabolite + gastroprotective agent combination	Dihydrofolate reductase (methotrexate); prostaglandin E1 receptor (misoprostol)
Zinc-l-carnosine	Zinc-l-carnosine	Fondazione IRCCS Policlinico San Matteo di Pavia	marketed	Mucosal protectant / Gastroprotective agent
CHOP Plus Famotidine	CHOP Plus Famotidine	Sherief Abd-Elsalam	phase 3	Combination chemotherapy with gastroprotective agent
Ibuprofen/famotidine	Ibuprofen/famotidine	Amgen	phase 3	NSAID with gastroprotective agent	COX-1/COX-2 (ibuprofen); H2 histamine receptor (famotidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gastroprotective agent class)

Bausch & Lomb Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ecabet 3.70% — Competitive Intelligence Brief. https://druglandscape.com/ci/ecabet-3-70. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing